New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
07:58 EDTPCYCPharmacyclics pullback makes it attractive, says Brean Capital
Brean Capital said the pullback in Pharmacyclics had made it one of the most attractive investment opportunities in its space. The firm cited positive Phase 3 studies for ibrutinib which highlighted its potential as a front line therapy in the next 3-4 years. Shares are Buy rated with an $80 price target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use